|
Gilbert, P B; Chiu, Y-L; Allen, M et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-47
|
|
Evans, T G; McElrath, M J; Matthews, T et al. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19:2080-91
|
|
Graham, B S; Keefer, M C; McElrath, M J et al. (1996) Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 125:270-9
|
|
Graham, B S (1994) Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 10 Suppl 2:S145-8
|
|
Warren, J T; Dolatshahi, M (1994) Annual updated survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol 23:184-225
|
|
Warren, J T; Dolatshahi, M (1993) First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies. J Med Primatol 22:203-35
|
|
Warren, J T; Dolatshahi, M (1992) Worldwide survey of AIDS vaccine challenge studies in nonhuman primates: vaccines associated with active and passive immune protection from live virus challenge. J Med Primatol 21:139-86
|
